---
title: "Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286811952.md"
description: "Phase 2 trial results have revealed that efdoralprin alfa showed superior performance compared to standard-of-care augmentation therapy in increasing fAAT levels in patients with AATD. The data highlights the efficacy of efdoralprin alfa in achieving higher levels of fAAT."
datetime: "2026-05-18T19:32:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286811952.md)
  - [en](https://longbridge.com/en/news/286811952.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286811952.md)
---

# Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD

Phase 2 trial results have revealed that efdoralprin alfa showed superior performance compared to standard-of-care augmentation therapy in increasing fAAT levels in patients with AATD. The data highlights the efficacy of efdoralprin alfa in achieving higher levels of fAAT.

### Related Stocks

- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)
- [159102.CN](https://longbridge.com/en/quote/159102.CN.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [516500.CN](https://longbridge.com/en/quote/516500.CN.md)
- [IXJ.AU](https://longbridge.com/en/quote/IXJ.AU.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [159859.CN](https://longbridge.com/en/quote/159859.CN.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [159892.CN](https://longbridge.com/en/quote/159892.CN.md)
- [588250.CN](https://longbridge.com/en/quote/588250.CN.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [ATS.US](https://longbridge.com/en/quote/ATS.US.md)

## Related News & Research

- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)
- [Kane Biotech Presents Data To Global Wound Care Community at WCET®–NSWOCC® 2026 Joint Congress | KNBIF Stock News](https://longbridge.com/en/news/286251150.md)
- [REGENXBIO Advances Duchenne Gene Therapy Toward Accelerated Approval](https://longbridge.com/en/news/286443456.md)
- [<![CDATA[Pharmaceutical Executive Daily: FDA Approves Baxdrostat]]>](https://longbridge.com/en/news/286807703.md)
- [Genprex data shows gene therapy reverses hyperglycemia in T2D mice at ASGCT](https://longbridge.com/en/news/286414681.md)